Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Spigel

Showing results (141-150 of 211) with videos related to

Pageof 22
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2012
International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1Giorgio V Scagliotti, Ihor Vynnychenko, Keunchil Park, et al.
Lung Cancer (Amsterdam, Netherlands)|August 9, 2021
Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancerByoung Chul Cho, Kiyotaka Yoh, Ruth Perets, et al.
The Lancet. Oncology|March 13, 2019
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket studyFunda Meric-Bernstam, Herbert Hurwitz, Kanwal Pratap Singh Raghav, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2024
RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung CancerDavid R Spigel, Afshin Dowlati, Yuanbin Chen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 15, 2021
Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLCJacek Jassem, Filippo de Marinis, Giuseppe Giaccone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2023
Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical TrialEdward B Garon, Shun Lu, Yasushi Goto, et al.
European Journal of Cancer (Oxford, England : 1990)|August 5, 2018
Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I studyLeora Horn, Scott N Gettinger, Michael S Gordon, et al.
Molecular Oncology|May 28, 2025
Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumabCharles Swanton, Russell W Madison, Candice Francheska B Tambaoan, et al.
The Lancet. Oncology|June 13, 2017
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trialAlice T Shaw, Tae Min Kim, Lucio Crinò, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2014
Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancerJoachim von Pawel, Robert Jotte, David R Spigel, et al.
Pageof 22

Showing results (141-150 of 211) with videos related to

Sort By:
Pageof 22
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2012
International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1Giorgio V Scagliotti, Ihor Vynnychenko, Keunchil Park, et al.
Lung Cancer (Amsterdam, Netherlands)|August 9, 2021
Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancerByoung Chul Cho, Kiyotaka Yoh, Ruth Perets, et al.
The Lancet. Oncology|March 13, 2019
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket studyFunda Meric-Bernstam, Herbert Hurwitz, Kanwal Pratap Singh Raghav, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2024
RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung CancerDavid R Spigel, Afshin Dowlati, Yuanbin Chen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 15, 2021
Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLCJacek Jassem, Filippo de Marinis, Giuseppe Giaccone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2023
Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical TrialEdward B Garon, Shun Lu, Yasushi Goto, et al.
European Journal of Cancer (Oxford, England : 1990)|August 5, 2018
Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I studyLeora Horn, Scott N Gettinger, Michael S Gordon, et al.
Molecular Oncology|May 28, 2025
Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumabCharles Swanton, Russell W Madison, Candice Francheska B Tambaoan, et al.
The Lancet. Oncology|June 13, 2017
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trialAlice T Shaw, Tae Min Kim, Lucio Crinò, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2014
Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancerJoachim von Pawel, Robert Jotte, David R Spigel, et al.
Pageof 22